{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:05:05Z","timestamp":1759939505763},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s12325-008-0070-6","type":"journal-article","created":{"date-parts":[[2008,6,21]],"date-time":"2008-06-21T02:11:36Z","timestamp":1214014296000},"page":"525-551","source":"Crossref","is-referenced-by-count":11,"title":["Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg\/NETA 0.1 mg"],"prefix":"10.1007","volume":"25","author":[{"given":"Odd Erik","family":"Johansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Qvigstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,6,21]]},"reference":[{"key":"70_CR1","unstructured":"United Common Database. Available at: http:\/\/unstats.un.org\/unsd\/cdb\/cdb_series_xrxx.asp?series_code=13630 . Accessed 10 January 2008."},{"key":"70_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"J.E. Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA. 2002;288:321\u2013333.","journal-title":"JAMA"},{"key":"70_CR3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1447-0756.2006.00402.x","volume":"32","author":"N.B. Topal","year":"2006","unstructured":"Topal NB, Ayhan S, Topal U, Bilgin T. Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins. J Obstet Gynaecol Res. 2006;32:305\u2013308.","journal-title":"J Obstet Gynaecol Res"},{"key":"70_CR4","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ijc.22437","volume":"120","author":"Y. Bremnes","year":"2007","unstructured":"Bremnes Y, Ursin G, Bjurstam N, Lund E, Gram IT. Different types of postmenopausal hormone therapy and mammographic density in Norwegian women. Int J Cancer. 2007;120:880\u2013884.","journal-title":"Int J Cancer"},{"key":"70_CR5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(96)07114-0","volume":"348","author":"H. Jick","year":"1996","unstructured":"Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981\u2013983.","journal-title":"Lancet"},{"issue":"1","key":"70_CR6","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1550-8579(05)80061-0","volume":"2","author":"O. Wu","year":"2005","unstructured":"Wu O. Postmenopausal hormone replacement therapy and venous thromboembolism. Gend Med. 2005;2(suppl 1):S18\u2013S27.","journal-title":"Gend Med"},{"key":"70_CR7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(96)07113-9","volume":"348","author":"E. Daly","year":"1996","unstructured":"Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977\u2013980.","journal-title":"Lancet"},{"key":"70_CR8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.7326\/0003-4819-133-12-200012190-00008","volume":"133","author":"F. Grodstein","year":"2000","unstructured":"Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933\u2013941.","journal-title":"Ann Intern Med"},{"key":"70_CR9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/1369713042000255688","volume":"7","author":"H. Burger","year":"2004","unstructured":"Burger H, Archer D, Barlow D, et al. Practical recommendations for hormone replacement therapy in the peri-and postmenopause. Climacteric. 2004;7:210\u2013216.","journal-title":"Climacteric"},{"key":"70_CR10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13697130310001651436","volume":"7","author":"S.H. Pedersen","year":"2004","unstructured":"Pedersen SH, Pedersen NG, Dalsgaard T, Lund CO, Nilas L, Ottesen B. Different cerebrovascular effects of medroxyprogesterone acetate and norethisterone acetate in the New Zealand white rabbit. Climacteric. 2004;7:12\u201322.","journal-title":"Climacteric"},{"key":"70_CR11","volume-title":"CHMP guideline on clinical investigations of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women","author":"European Medicines Agency.","year":"2005","unstructured":"European Medicines Agency. CHMP guideline on clinical investigations of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. Document ref: EMEA\/CHMP\/021\/97 rev 1. London: EMEA; 13 October 2005. Available at: http:\/\/www.tga.gov.au\/docs\/pdf\/euguide\/emea\/002197enrev1.pdf ."},{"key":"70_CR12","volume-title":"Recommendations for clinical evaluation","author":"FoodDrug Administration.","year":"2003","unstructured":"Food and Drug Administration. Guidance for industry. Estrogen and estrogen\/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms. Recommendations for clinical evaluation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); January 2003."},{"key":"70_CR13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13697130701361657","volume":"10","author":"Board of the International Menopause Society.","year":"2007","unstructured":"Board of the International Menopause Society. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007;10:181\u2013194.","journal-title":"Climacteric"},{"key":"70_CR14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/gme.0b013e31803167ab","volume":"14","author":"North American Menopause Society.","year":"2007","unstructured":"North American Menopause Society. Estrogen and progestogen use in peri-and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause. 2007;14:168\u2013182.","journal-title":"Menopause"},{"key":"70_CR15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/humupd\/8.2.155","volume":"8","author":"N. Santoro","year":"2002","unstructured":"Santoro N. The menopause transition: an update. Hum Reprod Update. 2002;8:155\u2013160.","journal-title":"Hum Reprod Update"},{"key":"70_CR16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/01.GME.0000135247.11972.B3","volume":"12","author":"K. R\u00f6dstr\u00f6m","year":"2005","unstructured":"R\u00f6dstr\u00f6m K, Bengtsson C, Lissner L, Bj\u00f6rkelund C. Reproducibility of selfreported menopause age at the 24-year follow-up of a population study of women in G\u00f8teborg, Sweden. Menopause. 2005;12:275\u2013280.","journal-title":"Menopause"},{"key":"70_CR17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/00016348109158130","volume":"60","author":"C. Bengtsson","year":"1981","unstructured":"Bengtsson C, Lindquist O, Redvall L. Menstrual status and menopausal age of middle-aged Swedish women. A population study of women in G\u00f8teborg 1968\u201369 and 1974\u201375. Acta Obstet Gynecol Scand. 1981;60:269\u2013275.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"70_CR18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0378-5122(84)90007-0","volume":"6","author":"M. Hammar","year":"1984","unstructured":"Hammar M, Berg G, F\u00e5hraeus L, Larsson-Cohn U. Climacteric symptoms in an unselected sample of Swedish women. Maturitas. 1984;6:345\u2013350.","journal-title":"Maturitas"},{"key":"70_CR19","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(02)11774-0","volume":"360","author":"V. Stearns","year":"2002","unstructured":"Stearns V, Ullmer L\u00f3pez JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet. 2002;360:1851\u20131861.","journal-title":"Lancet"},{"key":"70_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/fampra\/18.2.189","volume":"18","author":"L.W. Maartens","year":"2001","unstructured":"Maartens LW, Leusink GL, Knottnerus JA, Smeets CG, Pop VJ. Climacteric complaints in the community. Fam Pract. 2001;18:189\u2013194.","journal-title":"Fam Pract"},{"key":"70_CR21","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2105\/AJPH.91.9.1435","volume":"91","author":"J.T. Bromberger","year":"2001","unstructured":"Bromberger JT, Meyer PM, Kravitz HM, et al. Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health. 2001;91:1435\u20131442.","journal-title":"Am J Public Health"},{"key":"70_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1098-3597(99)90035-2","volume":"1","author":"R.B. Lipton","year":"1999","unstructured":"Lipton RB, Goadsby P, Silberstein SD. Classification and epidemiology of headache. Clin Cornerstone. 1999;1:1\u201310.","journal-title":"Clin Cornerstone"},{"key":"70_CR23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.AOG.0000270153.59102.40","volume":"110","author":"E.W. Freeman","year":"2007","unstructured":"Freeman EW, Sammel MD, Lin H, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol. 2007;110:230\u2013240.","journal-title":"Obstet Gynecol"},{"key":"70_CR24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1089\/jwh.2006.0138","volume":"16","author":"N.F. Woods","year":"2007","unstructured":"Woods NF, Smith-DiJulio K, Percival DB, Tao EY, Taylor HJ, Mitchell ES. Symptoms during the menopausal transition and early postmenopause and their relation to endocrine levels over time: observations from the Seattle Midlife Women\u2019s Health Study. J Womens Health. 2007;16:667\u2013677.","journal-title":"J Womens Health"},{"key":"70_CR25","first-page":"351","volume":"96","author":"L. Dennerstein","year":"2000","unstructured":"Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96:351\u2013358.","journal-title":"Obstet Gynecol"},{"key":"70_CR26","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0015-0282(01)01978-1","volume":"76","author":"L. Dennerstein","year":"2001","unstructured":"Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril. 2001;76:456\u2013460.","journal-title":"Fertil Steril"},{"key":"70_CR27","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJMoa067423","volume":"357","author":"S.T. Lindau","year":"2007","unstructured":"Lindau ST, Schumm LP, Laumann EO, Levinson W, O\u2019Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357:762\u2013774.","journal-title":"N Engl J Med"},{"key":"70_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0950-351X(05)80268-X","volume":"7","author":"N.E. Avis","year":"1993","unstructured":"Avis NE, Kaufert PA, Lock M, McKinlay SM, Vass K. The evolution of menopausal symptoms. Baillieres Clin Endocrinol Metab. 1993;7:17\u201332.","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"70_CR29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2004.09.016","volume":"58","author":"M. Kumari","year":"2005","unstructured":"Kumari M, Stafford M, Marmot M. The menopausal transition was associated in a prospective study with decreased health functioning in women who report menopausal symptoms. J Clin Epidemiol. 2005;58:719\u2013727.","journal-title":"J Clin Epidemiol"},{"key":"70_CR30","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0277-9536(01)00326-4","volume":"55","author":"R. Hardy","year":"2002","unstructured":"Hardy R, Kuh D. Change in psychological and vasomotor symptom reporting during the menopause. Soc Sci Med. 2002;55:1975\u20131988.","journal-title":"Soc Sci Med"},{"key":"70_CR31","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/0140-6736(91)93068-K","volume":"337","author":"M.G. Marmot","year":"1991","unstructured":"Marmot MG, Stansfeld S, Patel C, et al. Health inequalities among British civil servants: the Whitehall II study. Lancet. 1991;337:1387\u20131393.","journal-title":"Lancet"},{"key":"70_CR32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/bmj.307.6908.836","volume":"307","author":"E. Daly","year":"1993","unstructured":"Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ. 1993;307:836\u2013840.","journal-title":"BMJ"},{"key":"70_CR33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-5122(88)90022-9","volume":"10","author":"G. Berg","year":"1988","unstructured":"Berg G, Gottwall T, Hammar M, Lindgren R, Gottgall T. Climacteric symptoms among women aged 60\u201362 in Link\u00f8ping, Sweden, in 1986. Maturitas. 1988;10:193\u2013199.","journal-title":"Maturitas"},{"key":"70_CR34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00042192-200205000-00003","volume":"9","author":"K. R\u00f6dstr\u00f6m","year":"2002","unstructured":"R\u00f6dstr\u00f6m K, Bengtsson C, Lissner L, Milsom I, Sundh V, Bj\u00f6rkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause. 2002;9:156\u2013161.","journal-title":"Menopause"},{"key":"70_CR35","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1089\/jwh.1998.7.1149","volume":"7","author":"C.A. Staropoli","year":"1998","unstructured":"Staropoli CA, Flaws JA, Bush TL, Moulton AW. Predictors of menopausal hot flashes. J Womens Health. 1998;7:1149\u20131155.","journal-title":"J Womens Health"},{"key":"70_CR36","first-page":"264","volume":"101","author":"M.K. Whiteman","year":"2003","unstructured":"Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol. 2003;101:264\u2013272.","journal-title":"Obstet Gynecol"},{"key":"70_CR37","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0002-9378(03)00872-X","volume":"189","author":"C. Li","year":"2003","unstructured":"Li C, Samsioe G, Borgfeldt C, Lidfeldt J, Agardh CD, Nerbrand C. Menopause-related symptoms: what are the background factors? A prospective population-based cohort study of Swedish women (the Women\u2019s Health in Lund Area study). Am J Obstet Gynecol. 2003;189:1646\u20131653.","journal-title":"Am J Obstet Gynecol"},{"key":"70_CR38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00042192-200205000-00001","volume":"9","author":"R.R. Freedman","year":"2002","unstructured":"Freedman RR. Hot flash trends and mechanisms. Menopause. 2002;9:151\u2013152.","journal-title":"Menopause"},{"key":"70_CR39","first-page":"804","volume":"95","author":"M. Leal","year":"2000","unstructured":"Leal M, Diaz J, Serrano E, Abellan J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet Gynecol. 2000;95:804\u2013809.","journal-title":"Obstet Gynecol"},{"key":"70_CR40","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.298.6686.1488","volume":"298","author":"J. Ginsburg","year":"1989","unstructured":"Ginsburg J, Hardiman P, O\u2019Reilly B. Peripheral blood flow in menopausal women who have hot flushes and in those who do not. BMJ. 1989;298:1488\u20131490.","journal-title":"BMJ"},{"key":"70_CR41","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0002-9378(12)90817-0","volume":"168","author":"A. Oldenhave","year":"1993","unstructured":"Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993;168:772\u2013780.","journal-title":"Am J Obstet Gynecol"},{"key":"70_CR42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/00016348409155509","volume":"63","author":"C. Iosif","year":"1984","unstructured":"Iosif C, Bekassy Z. Prevalence of genitourinary symptoms in the late menopause. Acta Obstet Gynecol Scand. 1984;63:257\u2013260.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"70_CR43","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","volume":"286","author":"E.S. Siris","year":"2001","unstructured":"Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286:2815\u20132822.","journal-title":"JAMA"},{"key":"70_CR44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jwh.2006.0207","volume":"16","author":"F.K. Welty","year":"2007","unstructured":"Welty FK, Lee KS, Lew NS, Nasca M, Zhou JR. The association between soy nut consumption and decreased menopausal symptoms. J Womens Health. 2007;16:361\u2013369.","journal-title":"J Womens Health"},{"key":"70_CR45","doi-asserted-by":"crossref","unstructured":"Lethaby A, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007;(4):CD001395.","DOI":"10.1002\/14651858.CD001395.pub3"},{"key":"70_CR46","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMcp054015","volume":"355","author":"D. Grady","year":"2006","unstructured":"Grady D. Management of menopausal symptoms. N Engl J Med. 2006;355:2338\u20132347.","journal-title":"N Engl J Med"},{"key":"70_CR47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/00016349009013303","volume":"69","author":"M. Hammar","year":"1990","unstructured":"Hammar M, Berg G, Lindgren R. Does physical exercise influence the frequency of postmenopausal hot flushes? Acta Obstet Gynecol Scand. 1990;69:409\u2013412.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"70_CR48","doi-asserted-by":"crossref","unstructured":"Daley A, Macarthur C, Mutrie N, Stokes-Lampard H. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007(4):CD006108.","DOI":"10.1002\/14651858.CD006108.pub2"},{"key":"70_CR49","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1001\/jama.295.17.2057","volume":"295","author":"H.D. Nelson","year":"2006","unstructured":"Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295:2057\u20132071.","journal-title":"JAMA"},{"key":"70_CR50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.AOG.0000297371.89129.b3","volume":"111","author":"L. Speroff","year":"2008","unstructured":"Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111:77\u201387.","journal-title":"Obstet Gynecol"},{"key":"70_CR51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/09513599809015548","volume":"12","author":"J.M. Rymer","year":"1998","unstructured":"Rymer JM. The effects of tibolone. Gynecol Endocrinol. 1998;12:213\u2013220.","journal-title":"Gynecol Endocrinol"},{"key":"70_CR52","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1345\/aph.1D462","volume":"38","author":"J.M. Swegle","year":"2004","unstructured":"Swegle JM, Kelly MW. Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother. 2004;38:874\u2013881.","journal-title":"Ann Pharmacother"},{"key":"70_CR53","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-62-3-536","volume":"62","author":"B. Lignieres De","year":"1986","unstructured":"De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17 in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab. 1986;62:536\u2013541.","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR54","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1002\/j.1552-4604.1995.tb04143.x","volume":"35","author":"M.B. O\u2019Connell","year":"1995","unstructured":"O\u2019Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995;35(suppl):S18\u2013S24.","journal-title":"J Clin Pharmacol"},{"key":"70_CR55","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/0002-9378(88)90591-1","volume":"159","author":"F.Z. Stanczyk","year":"1998","unstructured":"Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol. 1998;159:1540\u20131546.","journal-title":"Am J Obstet Gynecol"},{"key":"70_CR56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0378-5122(94)90098-1","volume":"20","author":"Y. Frenkel","year":"1994","unstructured":"Frenkel Y, Kopernik G, Lazer S, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas. 1994;20:31\u201336.","journal-title":"Maturitas"},{"key":"70_CR57","first-page":"5","volume":"38","author":"The Transdermal HRT Investigators Group.","year":"1993","unstructured":"The Transdermal HRT Investigators Group. A randomized study to compare the effectiveness, tolerability and acceptability of two different transdermal estradiol replacement therapies. Int J Fertil Menopausal Stud. 1993;38:5\u201311.","journal-title":"Int J Fertil Menopausal Stud"},{"key":"70_CR58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0378-5122(00)00158-4","volume":"36","author":"L. Mosekilde","year":"2000","unstructured":"Mosekilde L, Beck-Nielsen H, S\u00f8rensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women-results of the Danish Osteoporosis Prevention Study. Maturitas. 2000;36:181\u2013193.","journal-title":"Maturitas"},{"key":"70_CR59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2362.1980.tb00033.x","volume":"10","author":"C. Christiansen","year":"1980","unstructured":"Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund KE, Transb\u00f8l I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest. 1980;10:273\u2013279.","journal-title":"Eur J Clin Invest"},{"key":"70_CR60","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.287.20.2668","volume":"287","author":"R. Lindsay","year":"2002","unstructured":"Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668\u20132676.","journal-title":"JAMA"},{"key":"70_CR61","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/01.AOG.0000137833.43248.79","volume":"104","author":"B. Ettinger","year":"2004","unstructured":"Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104:443\u2013451.","journal-title":"Obstet Gynecol"},{"key":"70_CR62","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.maturitas.2007.10.007","volume":"59","author":"M. Gambacciani","year":"2008","unstructured":"Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas. 2008;59:2\u20136.","journal-title":"Maturitas"},{"key":"70_CR63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09513590310001651722","volume":"18","author":"M. Gambacciani","year":"2004","unstructured":"Gambacciani M, Ciaponi M, Cappagli B, et al. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gynecol Endocrinol. 2004;18:9\u201316.","journal-title":"Gynecol Endocrinol"},{"key":"70_CR64","first-page":"4462","volume":"85","author":"K.M. Prestwood","year":"2000","unstructured":"Prestwood KM, Kenny AM, Unson C, Kulldorff M. The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab. 2000;85:4462\u20134469.","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR65","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.maturitas.2007.03.005","volume":"57","author":"H.S. Salminen","year":"2007","unstructured":"Salminen HS, S\u00e4\u00e4f ME, Johansson SE, Ringertz H, Strender LE. The effect of transvaginal estradiol on bone in aged women: a randomised controlled trial. Maturitas. 2007;57:370\u2013381.","journal-title":"Maturitas"},{"key":"70_CR66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0378-5122(96)01069-9","volume":"26","author":"J. Nathorst-B\u00f6\u00f6s","year":"1997","unstructured":"Nathorst-B\u00f6\u00f6s J, Hammar M. Effect on sexual life \u2014 a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas. 1997;26:15\u201320.","journal-title":"Maturitas"},{"key":"70_CR67","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/01.AOG.0000254160.62588.41","volume":"109","author":"J.A. Simon","year":"2007","unstructured":"Simon JA, Bouchard C, Waldbaum A, et al. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007;109:588\u2013596.","journal-title":"Obstet Gynecol"},{"key":"70_CR68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/gme.0b013e31805170eb","volume":"14","author":"The North American Menopause Society.","year":"2007","unstructured":"The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14:357\u2013369.","journal-title":"Menopause"},{"key":"70_CR69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.AOG.0000296714.12226.0f","volume":"111","author":"G. Bachmann","year":"2008","unstructured":"Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111:67\u201376.","journal-title":"Obstet Gynecol"},{"key":"70_CR70","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0378-5122(02)00327-4","volume":"44","author":"M. Gambacciani","year":"2003","unstructured":"Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas. 2003;44:157\u2013163.","journal-title":"Maturitas"},{"key":"70_CR71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/cmt.5.3.211.216","volume":"5","author":"H.P.G. Schneider","year":"2002","unstructured":"Schneider HPG. The view of the International Menopause Society on the Women\u2019s Health Initiative. Climacteric. 2002;5:211\u2013216.","journal-title":"Climacteric"},{"key":"70_CR72","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13697130400014615","volume":"7","author":"F. Naftolin","year":"2004","unstructured":"Naftolin F, Schneider HP, Sturdee D, et al. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric. 2004;7:333\u2013337.","journal-title":"Climacteric"},{"key":"70_CR73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0378-5122(96)82007-X","volume":"24","author":"J.R. Hilditch","year":"1996","unstructured":"Hilditch JR, Lewis J, Ross AH, et al. A comparison of the effects of oral copjugated equine estrogen and transdermal estradiol-17beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas. 1996;24:177\u2013184.","journal-title":"Maturitas"},{"key":"70_CR74","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1471-0528.1997.tb10945.x","volume":"104","author":"N. Zethraeus","year":"1997","unstructured":"Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol. 1997;104:1191\u20131195.","journal-title":"Br J Obstet Gynaecol"},{"key":"70_CR75","doi-asserted-by":"crossref","unstructured":"Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD003122.","DOI":"10.1002\/14651858.CD003122.pub2"},{"key":"70_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-138-1-200301070-00005","volume":"138","author":"A.M. Kanaya","year":"2003","unstructured":"Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen\/progestin replacement study \u2014 a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1\u20139.","journal-title":"Ann Intern Med"},{"key":"70_CR77","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00125-004-1448-x","volume":"47","author":"K.L. Margolis","year":"2004","unstructured":"Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women\u2019s Health Initiative Hormone Trial. Diabetologia. 2004;47:1175\u20131187.","journal-title":"Diabetologia"},{"key":"70_CR78","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2337\/diacare.24.7.1144","volume":"24","author":"A. Ferrara","year":"2001","unstructured":"Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: the Northern California Kaiser Permanente Diabetes Registry. Diabetes Care. 2001;24:1144\u20131150.","journal-title":"Diabetes Care"},{"key":"70_CR79","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJM197512042932303","volume":"293","author":"H.K. Ziel","year":"1975","unstructured":"Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293:1167\u20131170.","journal-title":"N Engl J Med"},{"key":"70_CR80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJM200107053450106","volume":"345","author":"J.E. Manson","year":"2001","unstructured":"Manson JE, Martin KA. Postmenopausal hormone-replacement therapy. N Engl J Med. 2001;345:34\u201340.","journal-title":"N Engl J Med"},{"key":"70_CR81","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/S0140-6736(98)10233-7","volume":"353","author":"E. Weiderpass","year":"1999","unstructured":"Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet. 1999;353:1824\u20131828.","journal-title":"Lancet"},{"key":"70_CR82","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0015-0282(16)49880-8","volume":"46","author":"R.J. King","year":"1986","unstructured":"King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril. 1986;46:1062\u20131066.","journal-title":"Fertil Steril"},{"key":"70_CR83","first-page":"373","volume":"96","author":"R.J. Kurman","year":"2000","unstructured":"Kurman RJ, F\u00e9lix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol. 2000;96:373\u2013379.","journal-title":"Obstet Gynecol"},{"key":"70_CR84","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1471-0528.2000.tb11654.x","volume":"107","author":"D.W. Sturdee","year":"2000","unstructured":"Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG. 2000;107:1392\u20131400.","journal-title":"BJOG"},{"key":"70_CR85","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mob.2002.122852","volume":"187","author":"B.J. Riis","year":"2002","unstructured":"Riis BJ, Lehmann HJ, Christiansen C. Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review. Am J Obstet Gynecol. 2002;187:1101\u20131116.","journal-title":"Am J Obstet Gynecol"},{"key":"70_CR86","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/humrep\/dei043","volume":"20","author":"M. Dietel","year":"2005","unstructured":"Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod. 2005;20:2052\u20132060.","journal-title":"Hum Reprod"},{"key":"70_CR87","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/humrep\/deg406","volume":"18","author":"K. Machens","year":"2003","unstructured":"Machens K, Schmidt-Gollwitzer K. Issues to debate on the Women\u2019s Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma? Hum Reprod. 2003;18:1992\u20131999.","journal-title":"Hum Reprod"},{"key":"70_CR88","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0015-0282(02)04403-5","volume":"78","author":"P.G. McDonough","year":"2002","unstructured":"McDonough PG. The randomized world is not without its imperfections: reflections on the Women\u2019s Health Initiative study. Fertil Steril. 2002;78:951\u2013956.","journal-title":"Fertil Steril"},{"key":"70_CR89","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/cmt.6.4.302.313","volume":"6","author":"S. Shapiro","year":"2003","unstructured":"Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women\u2019s Health Initiative randomized controlled trial. Climacteric. 2003;6:302\u2013310.","journal-title":"Climacteric"},{"key":"70_CR90","first-page":"e023","volume":"4","author":"J.H. Clark","year":"2006","unstructured":"Clark JH. A critique of Women\u2019s Health Initiative studies (2002\u20132006). Nucl Recept Signal. 2006;4:e023.","journal-title":"Nucl Recept Signal"},{"key":"70_CR91","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/13697130601012061","volume":"9","author":"S. Shapiro","year":"2006","unstructured":"Shapiro S. Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women\u2019s Health Initiative studies. Climacteric. 2006;9:416\u2013420.","journal-title":"Climacteric"},{"key":"70_CR92","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1080\/00016340701505523","volume":"86","author":"E. L\u00f8kkegaard","year":"2007","unstructured":"L\u00f8kkegaard E, Lidegaard O, M\u00f8ller LN, Agger C, Andreasen AH, J\u00f8rgensen T. Hormone replacement therapy in Denmark, 1995\u20132004. Acta Obstet Gynecol Scand. 2007;86:1342\u20131351.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"70_CR93","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11096-007-9115-1","volume":"29","author":"M.J. Tiihonen","year":"2007","unstructured":"Tiihonen MJ, Heikkinen AM, Ahonen RS. Do Finnish women using hormone replacement therapy need more information about risks? Pharm World Sci. 2007;29:635\u2013640.","journal-title":"Pharm World Sci"},{"key":"70_CR94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2296-7-61","volume":"7","author":"L.M. French","year":"2006","unstructured":"French LM, Smith MA, Holtrop JS, Holmes-Rovner M. Hormone therapy after the Women\u2019s Health Initiative: a qualitative study. BMC Fam Pract. 2006;7:61.","journal-title":"BMC Fam Pract"},{"key":"70_CR95","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1080\/00016340701745418","volume":"86","author":"A.T. Pedersen","year":"2007","unstructured":"Pedersen AT, Iversen OE, L\u00f8kkegaard E, et al. Impact of recent studies on attitudes and use of hormone therapy among Scandinavian gynaecologists. Acta Obstet Gynecol Scand. 2007;86:1490\u20131495.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"70_CR96","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","volume":"297","author":"J.E. Rossouw","year":"2007","unstructured":"Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465\u20131477.","journal-title":"JAMA"},{"key":"70_CR97","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMoa071513","volume":"356","author":"J.E. Manson","year":"2007","unstructured":"Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronaryartery calcification. N Engl J Med. 2007;356:2591\u20132602.","journal-title":"N Engl J Med"},{"key":"70_CR98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/jwh.2006.15.35","volume":"15","author":"F. Grodstein","year":"2006","unstructured":"Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health. 2006;15:35\u201344.","journal-title":"J Womens Health"},{"key":"70_CR99","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1525-1497.2006.00389.x","volume":"21","author":"S.R. Salpeter","year":"2006","unstructured":"Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. a meta-analysis. J Gen Intern Med. 2006;21:363\u2013266.","journal-title":"J Gen Intern Med"},{"key":"70_CR100","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/13697130600647743","volume":"9","author":"P. Alexandersen","year":"2006","unstructured":"Alexandersen P, Tank\u00f3 LB, Bagger YZ, Qin G, Christiansen C. The long-term impact of 2\u20133 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric. 2006;9:108\u2013118.","journal-title":"Climacteric"},{"key":"70_CR101","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1525-1497.2004.30281.x","volume":"19","author":"S.R. Salpeter","year":"2004","unstructured":"Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women. a meta-analysis. J Gen Intern Med. 2004;19:791\u2013804.","journal-title":"J Gen Intern Med"},{"key":"70_CR102","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0008-6363(01)00466-7","volume":"53","author":"T.S. Mikkola","year":"2002","unstructured":"Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res. 2002;53:605\u2013619.","journal-title":"Cardiovasc Res"},{"key":"70_CR103","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI27987","volume":"116","author":"B.J. Deroo","year":"2006","unstructured":"Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116:561\u2013570.","journal-title":"J Clin Invest"},{"key":"70_CR104","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/00365510601085951","volume":"67","author":"A.T. Henttonen","year":"2007","unstructured":"Henttonen AT, Kortelainen ML, Kunnas TA, Nikkari ST. Estrogen receptor-1 genotype is related to coronary intima thickness in young to middle-aged women. Scand J Clin Lab Invest. 2007;67:380\u2013386.","journal-title":"Scand J Clin Lab Invest"},{"key":"70_CR105","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"G.L. Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. JAMA. 2004;291:1701\u20131712.","journal-title":"JAMA"},{"key":"70_CR106","doi-asserted-by":"crossref","unstructured":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350:1047\u20131059.","DOI":"10.1016\/S0140-6736(97)08233-0"},{"key":"70_CR107","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/09513590701382104","volume":"23","author":"M. Espi\u00e9","year":"2007","unstructured":"Espi\u00e9 M, Daures JP, Chevallier T, Mares P, Micheletti MC, De-Reilhac P. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol. 2007;23:391\u2013397.","journal-title":"Gynecol Endocrinol"},{"key":"70_CR108","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/13697130400001380","volume":"7","author":"E.M. Durna","year":"2004","unstructured":"Durna EM, Heller GZ, Leader LR, Sjoblom P, Eden JA, Wren BG. Breast cancer in premenopausal women: recurrence and survival rates and relationship to hormone replacement therapy. Climacteric. 2004;7:284\u2013291.","journal-title":"Climacteric"},{"key":"70_CR109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5122(00)00150-X","volume":"36","author":"H.A. Verheul","year":"2000","unstructured":"Verheul HA, Coelingh-Bennink HJ, Kenemans P, et al. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas. 2000;36:1\u201317.","journal-title":"Maturitas"},{"key":"70_CR110","doi-asserted-by":"crossref","first-page":"342.e1","DOI":"10.1016\/j.ajog.2006.10.901","volume":"196","author":"F. Schuetz","year":"2007","unstructured":"Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol. 2007;196:342.e1\u2013e9.","journal-title":"Am J Obstet Gynecol"},{"key":"70_CR111","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/jnci\/djm062","volume":"99","author":"R.M. Tamimi","year":"2007","unstructured":"Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2007;99:1178\u20131187.","journal-title":"J Natl Cancer Inst"},{"key":"70_CR112","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00042192-199906030-00015","volume":"6","author":"B. Ettinger","year":"1999","unstructured":"Ettinger B. Personal perspective on lowdosage estrogen therapy for postmenopausal women. Menopause. 1999;6:273\u2013276.","journal-title":"Menopause"},{"key":"70_CR113","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0015-0282(98)00051-X","volume":"69","author":"C.T. Erel","year":"1998","unstructured":"Erel CT, Elter K, Akman C, et al. Mammographic changes in women receiving tibolone therapy. Fertil Steril. 1998;69:870\u2013875.","journal-title":"Fertil Steril"},{"key":"70_CR114","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0378-5122(01)00235-3","volume":"40","author":"C. Egarter","year":"2001","unstructured":"Egarter C, Eppel W, Vogel S, Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas. 2001;40:165\u2013171.","journal-title":"Maturitas"},{"key":"70_CR115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0301-2115(98)00129-8","volume":"80","author":"N. Colacurci","year":"1998","unstructured":"Colacurci N, Mele D, De-Franciscis P, Costa V, Fortunato N, De-Seta L. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol. 1998;80:235\u2013238.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"70_CR116","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1067\/mob.2002.121896","volume":"186","author":"E. Lundstr\u00f6m","year":"2002","unstructured":"Lundstr\u00f6m E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 2002;186:717\u2013722.","journal-title":"Am J Obstet Gynecol"},{"key":"70_CR117","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","volume":"362","author":"V. Beral","year":"2003","unstructured":"Beral V. Million Women Study Collaborators. Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet. 2003;362:419\u2013427.","journal-title":"Lancet"},{"key":"70_CR118","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/01.gme.0000247012.54468.75","volume":"14","author":"E.J. Velthuis-Te Wierik","year":"2007","unstructured":"Velthuis-Te Wierik EJ, Hendricks PT, Martinez C. Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women. Menopause. 2007;14:518\u2013527.","journal-title":"Menopause"},{"issue":"2","key":"70_CR119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.breast.2007.07.028","volume":"16","author":"E. Kubista","year":"2007","unstructured":"Kubista E, Kenemans P, Foidart JM, et al. Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients \u2014 design and baseline data \u2018LIBERATE\u2019 trial. Breast. 2007;16(suppl 2):182\u2013189.","journal-title":"Breast"},{"key":"70_CR120","unstructured":"International klimakteriestudie with breast cancer patients terminated prematurely [press release; in Swedish]. Gothenburg, Sweden: Organon Schering-Plough; 21 May 2007. Available at: http:\/\/www.organon.se\/news\/070521liberate.asp . Accessed 10 January 2008."},{"key":"70_CR121","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","volume":"362","author":"P.Y. Scarabin","year":"2003","unstructured":"Scarabin PY, Oger E, Plu-Bureau G. EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428\u2013432.","journal-title":"Lancet"},{"key":"70_CR122","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/01.CIR.103.5.638","volume":"103","author":"J.A. Simon","year":"2001","unstructured":"Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-Progestin Replacement Study (HERS). Circulation. 2001;103:638\u2013642.","journal-title":"Circulation"},{"key":"70_CR123","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa010534","volume":"345","author":"C.M. Viscoli","year":"2001","unstructured":"Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243\u20131249.","journal-title":"N Engl J Med"},{"key":"70_CR124","first-page":"726","volume":"95","author":"M. Notelovitz","year":"2000","unstructured":"Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000;95:726\u2013731.","journal-title":"Obstet Gynecol"},{"key":"70_CR125","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/j.1532-5415.2005.53567.x","volume":"53","author":"A.M. Kenny","year":"2005","unstructured":"Kenny AM, Kleppinger A, Wang Y, Prestwood KM. Effects of ultra-low-dose estrogen therapy on muscle and physical function in older women. J Am Geriatr Soc. 2005;53:1973\u20131977.","journal-title":"J Am Geriatr Soc"},{"key":"70_CR126","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0378-5122(01)00281-X","volume":"40","author":"M. Gambacciani","year":"2001","unstructured":"Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas. 2001;40:195\u2013201.","journal-title":"Maturitas"},{"key":"70_CR127","unstructured":"6th IMS Workshop web site. Available at: www.6thimsworkshop.com . Accessed 10 December 2007."},{"key":"70_CR128","unstructured":"Activella physician insert. Princeton, NJ: Novo Nordisk Inc; 2006. Available at: www.fda.gov\/cder\/foi\/label\/2006\/020907s009s011lbl.pdf . Accessed 10 January 2008."},{"key":"70_CR129","unstructured":"Activelle Produktresume [in Swedish]. Bagsv\u00e6rd, Denmark: Novo Nordisk A\/S; 2007. Available at: www.lakemedelsverket.se\/upload\/SPC_PIL\/Pdf\/humspc\/Activelle%2005mg01mg%20filmcoated%20tablet.pdf . Accessed 10 January 2008."},{"key":"70_CR130","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13697130701298107","volume":"10","author":"N. Panay","year":"2007","unstructured":"Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007;10:120\u2013131.","journal-title":"Climacteric"},{"key":"70_CR131","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/13697130701852390","volume":"11","author":"D.W. Sturdee","year":"2008","unstructured":"Sturdee DW, Archer DF, Rakov V, Lang E. CHOICE Study investigators. Ultra low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric. 2008;11:63\u201373.","journal-title":"Climacteric"},{"key":"70_CR132","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13697130701385805","volume":"10","author":"E. Lundstr\u00f6m","year":"2007","unstructured":"Lundstr\u00f6m E, Bygdeson M, Svane G, Azavedo E, von-Schoultz B. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric. 2007;10:249\u2013256.","journal-title":"Climacteric"},{"key":"70_CR133","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1471-0528.1998.tb10237.x","volume":"105","author":"M. Hammar","year":"1998","unstructured":"Hammar M, Christau S, Nathorst B, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998;105:904\u2013911.","journal-title":"Br J Obstet Gynaecol"},{"key":"70_CR134","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1471-0528.2007.01537.x","volume":"114","author":"M.L. Hammar","year":"2007","unstructured":"Hammar ML, van de Weijer P, Franke HR, et al. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG. 2007;114:1522\u20131529.","journal-title":"BJOG"},{"key":"70_CR135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.maturitas.2004.04.008","volume":"50","author":"H. Junkermann","year":"2005","unstructured":"Junkermann H, von-Holst T, Lang E, Rakov V. Influence of different HRT regimens on mammographic density. Maturitas. 2005;50:105\u2013110.","journal-title":"Maturitas"},{"key":"70_CR136","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0020-7292(00)00342-8","volume":"72","author":"S. Rozenberg","year":"2001","unstructured":"Rozenberg S, Caubel P, Lim PC. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. Int J Gynaecol Obstet. 2001;72:235\u2013243.","journal-title":"Int J Gynaecol Obstet"},{"key":"70_CR137","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0378-5122(01)00245-6","volume":"40","author":"M. Bruhat","year":"2001","unstructured":"Bruhat M, Rudolf K, Vaheri R, Kainulainen P, Timonen U, Viitanen A. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study. Maturitas. 2001;40:259\u2013271.","journal-title":"Maturitas"},{"key":"70_CR138","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.maturitas.2007.08.004","volume":"58","author":"J. Endrikat","year":"2007","unstructured":"Endrikat J, Graeser T, Mellinger U, Ertan K, Holz C. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate\/2mg dienogest on hot flushes in postmenopausal women. Maturitas. 2007;58:201\u2013207.","journal-title":"Maturitas"},{"key":"70_CR139","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.fertnstert.2004.02.096","volume":"81","author":"P. Conner","year":"2004","unstructured":"Conner P, Svane G, Azavedo E, et al. Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy. Fertil Steril. 2004;81:1617\u20131623.","journal-title":"Fertil Steril"},{"key":"70_CR140","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1258\/175404507781605596","volume":"13","author":"L.A. Mattsson","year":"2007","unstructured":"Mattsson LA, Skouby S, Rees M, et al. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women. Menopause Int. 2007;13:124\u2013131.","journal-title":"Menopause Int"},{"key":"70_CR141","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.maturitas.2007.03.004","volume":"57","author":"B.S. Lee","year":"2007","unstructured":"Lee BS, Kang BM, Yoon BK, Choi H, Park HM, Kim JG. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebocontrolled, multicenter study. Maturitas. 2007;57:361\u2013369.","journal-title":"Maturitas"},{"key":"70_CR142","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0015-0282(01)01791-5","volume":"75","author":"W.H. Utian","year":"2001","unstructured":"Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar J. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065\u20131079.","journal-title":"Fertil Steril"},{"key":"70_CR143","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0015-0282(01)01792-7","volume":"75","author":"D.F. Archer","year":"2001","unstructured":"Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 2001;75:1080\u20131087.","journal-title":"Fertil Steril"},{"key":"70_CR144","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0015-0282(01)01828-3","volume":"76","author":"J.H. Pickar","year":"2001","unstructured":"Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;76:25\u201331.","journal-title":"Fertil Steril"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-008-0070-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-008-0070-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-008-0070-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T07:55:51Z","timestamp":1559462151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-008-0070-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":144,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1007\/s12325-008-0070-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}